The GVDN™ is a technical partner with the COVID-19-SENT-[Africa-8], Sentinel surveillance of adverse events of special interest (AESIs) after vaccination with COVID-19 vaccines in African Advanced Market Commitment-92 eligible countries, project.* Hospital-based sentinel surveillance designed to detect safety signals of rare adverse events of special interest (AESIs) or to evaluate safety signals arising from other sources, following vaccination with COVID-19 vaccines, is being implemented in eight African AMC-92 countries in the Alive (African Leadership in Vaccinology Expertise) Network: